Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Tirzepatide | Retatrutide |
|---|---|---|
| Class | Dual GIP / GLP-1 receptor agonist | Triple GIP / GLP-1 / glucagon receptor agonist |
| Research category | type 2 diabetes and obesity | obesity and type 2 diabetes |
| Evidence level | High | Moderate |
| Overall status | Approved (Rx) — type 2 diabetes and chronic weight management | Not approved — phase 3 clinical research |
| FDA | Approved (Rx) | Not approved |
| EMA | Approved (Rx) | Not approved |
| WADA | Not listed — check current list | Check current list |
| Mechanism studied | Tirzepatide → GIPR + GLP-1R → Insulin & satiety signalling → Glucose & body-weight endpoints | Retatrutide → GIPR + GLP-1R + GCGR → Satiety & energy expenditure → Weight & liver-fat endpoints |
| Molecular weight | 4,813.5 g/mol | — |
| Sizes in stock | , , , , , | , , , , |
Where the research overlaps
Both compounds are studied within Metabolic & GLP-1 research. Tirzepatide is classed as dual gip / glp-1 receptor agonist, while Retatrutide is triple gip / glp-1 / glucagon receptor agonist. Evidence is rated high for Tirzepatide and moderate for Retatrutide.
For a full write-up, read Retatrutide Research Review: GIP, GLP-1 and Glucagon.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.